APA (7th ed.) Citation

Bröckelmann, P. J., Bühnen, I., Meißner, J., Trautmann-Grill, K., Herhaus, P., Halbsguth, T. V., . . . von Tresckow, B. (2023). Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma: Final analysis of the randomized German Hodgkin Study Group Phase II NIVAHL trial. Journal of clinical oncology, 41(6), . https://doi.org/10.1200/JCO.22.02355

Chicago Style (17th ed.) Citation

Bröckelmann, Paul Jan, et al. "Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial." Journal of Clinical Oncology 41, no. 6 (2023). https://doi.org/10.1200/JCO.22.02355.

MLA (9th ed.) Citation

Bröckelmann, Paul Jan, et al. "Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial." Journal of Clinical Oncology, vol. 41, no. 6, 2023, https://doi.org/10.1200/JCO.22.02355.